CONNECTA Therapeutics

About

CONNECTA Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain, founded in 2019. The company focuses on developing innovative treatments for Central Nervous System (CNS) disorders, particularly neurodevelopmental disorders such as Fragile X Syndrome (FXS). It employs a network pharmacology-based approach to identify multiple actionable targets, aiming to improve the lives of patients and families affected by these conditions. The company's lead candidate, CTH120, is a first-in-class small molecule designed to address neuroplasticity imbalances. It has shown promising preclinical efficacy in improving cognitive abilities and social behaviors in models of FXS and is advancing to Phase II clinical trials. Another candidate, CTH122, is a recently patented small molecule with similar properties and efficacy in preclinical models. CONNECTA Therapeutics emphasizes rigorous science and collaboration in its research and development efforts.